KLOW Blend

KLOW is a research-grade four-peptide blend combining GHK-Cu, BPC-157, KPV and TB-500 (80mg total), studied in preclinical models for tissue repair, anti-inflammatory biology, angiogenesis and gut barrier function.

Each component is studied for a complementary pathway. GHK-Cu is researched for stimulating collagen synthesis and dermal fibroblast activity. BPC-157 is studied for angiogenesis and tendon, ligament and gut repair. KPV is investigated for anti-inflammatory signalling via melanocortin pathways. TB-500 is studied for actin binding, cell migration and systemic tissue repair. Combined, the blend is researched for how these pathways interact in wound healing, angiogenesis and inflammatory models.

KLOW is a research-grade four-peptide blend combining GHK-Cu (50mg), BPC-157 (10mg), KPV (10mg) and TB-500 (10mg), supplied as 80mg total of lyophilised powder. It is formulated for laboratory research studying multi-peptide interaction analysis, signalling pathway investigation and combined tissue repair, anti-inflammatory and dermal biology in controlled experimental models. Each constituent has a substantial body of preclinical literature spanning angiogenesis, wound healing and gut barrier function.

Most data supporting the KLOW blend derives from preclinical (animal and in-vitro) studies of its individual constituents. Human clinical evidence for the combined formulation is limited and the blend is not a licensed medicine.